CHRO logo

Chromocell Therapeutics (CHRO) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 February 2024

Indexes:

Not included

Description:

Chromocell Therapeutics (CHRO) focuses on developing innovative therapies for pain and other conditions. The company uses advanced technologies to discover and create new drugs, aiming to improve patient outcomes and address unmet medical needs in the pharmaceutical industry.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

18 June '24 Alliance Global Partners
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Chromocell Announces Amendment to Stock Repurchase Plan
Chromocell Announces Amendment to Stock Repurchase Plan
Chromocell Announces Amendment to Stock Repurchase Plan
CHRO
globenewswire.com24 October 2024

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized an amendment (the “Amendment”) to the Company's existing stock repurchase plan (as amended, the “Repurchase Plan”) to increase the total value of shares of Chromocell's common stock (“Common Stock”) available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000.

Chromocell to Participate in Life Sciences Investor Forum September 19th
Chromocell to Participate in Life Sciences Investor Forum September 19th
Chromocell to Participate in Life Sciences Investor Forum September 19th
CHRO
globenewswire.com16 September 2024

FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024.

Chromocell Announces Stock Repurchase Plan
Chromocell Announces Stock Repurchase Plan
Chromocell Announces Stock Repurchase Plan
CHRO
globenewswire.com07 August 2024

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized a stock repurchase plan (the “Repurchase Plan”) of up to $250,000 of Chromocell's common stock (“Common Stock”), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Common Stock as of August 6, 2024. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.

Chromocell to Participate in the Virtual Investor Lunch Break Series
Chromocell to Participate in the Virtual Investor Lunch Break Series
Chromocell to Participate in the Virtual Investor Lunch Break Series
CHRO
globenewswire.com15 July 2024

Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET

Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
CHRO
businesswire.com31 May 2024

OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom” or the “Company”), a leading provider of comprehensive, cloud-based human capital management software, announced that Randy Peck, a 20-year Paycom veteran, has been appointed to serve as Paycom's Chief Operating Officer, while Matt Paque and Jennifer Kraszewski have been promoted to Chief Legal Officer and Chief Human Resources Officer, respectively. “These promotions align with our ambition to continue to help Paycom.

PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
CHRO
prnewswire.com22 May 2024

Briones and Carey to join company's executive committee on Jan. 1, 2025 SAN FRANCISCO , May 22, 2024 /PRNewswire/ -- Prologis (NYSE: PLD) today announced Ed Nekritz and Colleen McKeown will retire as chief legal officer and chief human resources officer, effective January 1, 2025.  Current Deputy General Counsel Deborah Briones and Senior Vice President of Human Resources Nathaalie Carey will succeed Nekritz and McKeown.

FAQ

  • What is the primary business of Chromocell Therapeutics?
  • What is the ticker symbol for Chromocell Therapeutics?
  • Does Chromocell Therapeutics pay dividends?
  • What sector is Chromocell Therapeutics in?
  • What industry is Chromocell Therapeutics in?
  • What country is Chromocell Therapeutics based in?
  • When did Chromocell Therapeutics go public?
  • Is Chromocell Therapeutics in the S&P 500?
  • Is Chromocell Therapeutics in the NASDAQ 100?
  • Is Chromocell Therapeutics in the Dow Jones?
  • When does Chromocell Therapeutics report earnings?
  • Should I buy Chromocell Therapeutics stock now?

What is the primary business of Chromocell Therapeutics?

Chromocell Therapeutics (CHRO) focuses on developing innovative therapies for pain and other conditions. The company uses advanced technologies to discover and create new drugs, aiming to improve patient outcomes and address unmet medical needs in the pharmaceutical industry.

What is the ticker symbol for Chromocell Therapeutics?

The ticker symbol for Chromocell Therapeutics is NYSE American:CHRO

Does Chromocell Therapeutics pay dividends?

No, Chromocell Therapeutics does not pay dividends

What sector is Chromocell Therapeutics in?

Chromocell Therapeutics is in the Healthcare sector

What industry is Chromocell Therapeutics in?

Chromocell Therapeutics is in the Biotechnology industry

What country is Chromocell Therapeutics based in?

Chromocell Therapeutics is headquartered in United States

When did Chromocell Therapeutics go public?

Chromocell Therapeutics's initial public offering (IPO) was on 16 February 2024

Is Chromocell Therapeutics in the S&P 500?

No, Chromocell Therapeutics is not included in the S&P 500 index

Is Chromocell Therapeutics in the NASDAQ 100?

No, Chromocell Therapeutics is not included in the NASDAQ 100 index

Is Chromocell Therapeutics in the Dow Jones?

No, Chromocell Therapeutics is not included in the Dow Jones index

When does Chromocell Therapeutics report earnings?

The date for Chromocell Therapeutics's next earnings report has not been announced yet

Should I buy Chromocell Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions